Blog

Oct 9, 2024, 07:16

Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients

Diego Prost, Medical oncologist and Neuro-oncology fellow at Pitié-Salpêtrière University Hospital, shared a post on X:

”Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review – ESMO Open.

Better outcomes are associated with histology, treatment response, and targeted therapy.

Proud to collaborate with Hospital Saint-Joseph and The National Cancer Institute of Milan.”

Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review

Authors: D. Prost, S. Iseas, M. Gatineau, J. Adam, S. Cavalieri, C. Bergamini, L. Licitra, É. Raymond.

Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients

Source: Diego Prost/X

C. Bergamini cancer D. Prost Diego Prost É. Raymond ESMO Open Histology Hospital Saint-Joseph J. Adam L. Licitra M. Gatineau OncoDaily Oncology S. Cavalieri S. Iseas Salivary Gland Cancer targeted therapy The National Cancer Institute of Milan treatment response

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage